Skip to main content
Sanofi's application for myeloma drug isatuximab accepted by FDA

The FDA has accepted for review Sanofi's marketing application for the use of its monoclonal antibody therapy isatuximab as a treatment for patients with relapsed/refractory multiple myeloma. The agency set the action date for April 30, 2020.

Full Story: